Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration
- 1 February 2002
- journal article
- research article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 25 (1), 1-5
- https://doi.org/10.1046/j.1365-2885.2002.00381.x
Abstract
The pharmacokinetics after oral application of the fluoroquinolones (FQs), enrofloxacin, difloxacin, marbofloxacin and orbifloxacin were compared in independent crossover studies in Beagle dogs. Commercially available tablet formulations were given at common dosage recommended by the manufacturers which were 2.0 mg/kg body weight (bw) for marbofloxacin, 2.5 mg/kg bw for orbifloxacin and 5.0 mg/kg bw for enrofloxacin and difloxacin. Analysis was performed by an agar diffusion assay. Pharmacokinetic parameters were calculated by noncompartmental methods. All FQs were rapidly absorbed and achieved average peak serum concentrations of 1.41, 1.11, 1.47 and 1.37 μg/mL for enrofloxacin, difloxacin, marbofloxacin and orbifloxacin, respectively. Enrofloxacin was eliminated at a terminal half‐life (t½) of 4.1 h, difloxacin at 6.9 h, orbifloxacin at 7.1 h and marbofloxacin at 9.1 h. While the area under the serum concentration–time curve of the 24‐h dosing interval (AUC0–24) for marbofloxacin and orbifloxacin were similar (approximately 13 μg · h/mL), enrofloxacin attained an AUC0–24 of 8.7 and difloxacin of 9.3 μg · h/mL. Because of its favourable pharmacokinetics combined with excellent in vitro activity, enrofloxacin exhibited superior pharmacodynamic predictors of in vivo antimicrobial activity as Cmax/MIC (maximum serum concentration/minimum inhibitory concentration) and AUC0–24/MIC (area under the 24‐h serum concentration–time curve/minimum inhibitory concentration) compared with other FQs.Keywords
This publication has 18 references indexed in Scilit:
- In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2001
- Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogsJournal of Veterinary Pharmacology and Therapeutics, 2000
- Pharmacokinetics and Pharmacodynamics of FluoroquinolonesDrugs, 1999
- Absorption, Distribution and Excretion of Orbifloxacin in Dogs and CatsJournal of the Japan Veterinary Medical Association, 1997
- Fluoroquinolones in animal healthJournal of Veterinary Pharmacology and Therapeutics, 1996
- Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administrationJournal of Veterinary Pharmacology and Therapeutics, 1996
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisAntimicrobial Agents and Chemotherapy, 1993
- Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophagesJournal of Antimicrobial Chemotherapy, 1990
- Fluoroquinolone antimicrobial agentsClinical Microbiology Reviews, 1989